QT Prolongation Risk Assessed for Non-SSRI Antidepressants

QT Prolongation Risk Assessed for Non-SSRI Antidepressants
QT Prolongation Risk Assessed for Non-SSRI Antidepressants
Although the FDA requires drug companies to do extensive side-effect testing on their products prior to approval, including QT and QTc prolongation testing, there is still a concern that products that make it to market may cause QT prolongation, and subsequently torsades de pointes.

Objective: To review QT prolongation potential with newer nonselective serotonin reuptake inhibitor (non-SSRI) antidepressants. Data Sources: A PubMed literature search was performed from 1982 through June 16, 2014. In elderly patients with a variety of high-risk comorbidities, mirtazapine did demonstrate higher odds of sudden cardiac death and ventricular arrhythmias when compared with paroxetine.

READ FULL ARTICLE Curated publisher From aop.sagepub.com

  • Latest News Your top articles for Wednesday

  • Haymarket Medical NetworkTop Picks

  • Loading...

    Continuing Medical Education (CME/CE) Courses

    Show More